Mixed Ovarian Carcinoma (MXOV)

Overview

Mixed Ovarian Carcinoma (MXOV) is an ovarian tumor composed of two or more distinct histological carcinoma types. It sits under the Ovarian Tumor parent node (OVT) in OncoTree and is classified within the Ovarian Cancer main type. The five ovarian carcinosarcoma cases in PMID:25233892 are coded as MXOV.

Cohorts in the corpus

• ucs_jhu_2014 — 5 ovarian carcinosarcoma samples profiled by whole-exome sequencing (part of a 22-sample gynaecologic carcinosarcoma cohort) PMID:25233892.

Recurrent alterations

• Whole-exome sequencing of 5 ovarian carcinosarcomas found high rates of ARID1A mutation (4/5 MSS cases, enriched relative to uterine primaries), along with TP53, PIK3CA, PTEN, KRAS, and chromatin-remodelling gene alterations consistent with the broader carcinosarcoma landscape; mismatch-repair–deficient tumours harboured extreme hypermutation (904–5,913 somatic alterations) PMID:25233892.

Subtypes

• Ovarian carcinosarcoma (malignant mixed Müllerian tumour of ovarian origin) — represents the five MXOV cases in the corpus; distinct from uterine carcinosarcoma (UCS) by ARID1A enrichment in MSS cases PMID:25233892.

Therapeutic landscape

• PI3K pathway hits (PIK3CA, PIK3R1, PTEN) in >50% of combined carcinosarcoma cases support PI3K/mTOR/AKT inhibitor trials; BRCA1/BRCA2 and FANCM defects suggest platinum and PARP inhibitor sensitivity; MMR-deficient cases are candidates for anti-PD-1 immunotherapy PMID:25233892.

Sources

• PMID:25233892 — Jones et al., whole-exome sequencing of 22 gynaecologic carcinosarcomas including 5 ovarian cases.

This page was processed by entity-page-writer on 2026-05-11.